Efficacy and safety of ofatumumab in Chinese participants with multiple sclerosis: results from a 12-month, prospective, open-label, multicenter study
Ofatumumab, a fully human anti-CD20 monoclonal antibody, has shown superior efficacy and a comparable overall safety profile to teriflunomide in the pivotal ASCLEPIOS I/II trials in people living with relapsing multiple sclerosis (plwRMS). However, data on the efficacy and safety of ofatumumab, a high-efficacy th...